In fact, the evidence from this and other studies [11–16, 18] suggests a possible role of decreased adiponectin levels in the pathophysiology of NAFLD, thus underlining the need for future large-scale studies assessing the predictive as well as the therapeutic role of this adipokine in the spectrum of NAFLD. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.